Back

Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

26 August 2023 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention: lipids (2) Drug therapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

8 More presentations in this session

Presentation thumbnail
Hyperlipoproteinemia(a) in coronary artery disease patients: who are patients with very high levels and how do they respond to the PCSK9 antibody therapy?
Doctor M. Novakovic (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
Prevalence and outcomes of familial hypercholesterolemia in young patients undergoing coronary bypass surgery
Doctor J. Black (Hobart, AU)
Abstract Slides Video
Presentation thumbnail
Increased triglyceride independently associates with premature structural and functional cardiac damage progression in asymptomatic adolescents: a 7-year longitudinal study
Doctor A. Agbaje (Kuopio, FI)
Abstract Slides Video
Presentation thumbnail
Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease
Doctor D. Shishikura (Takatsuki, JP)
Abstract Slides Video
Presentation thumbnail
Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study
Doctor I. Andrikou (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention: lipids (2)

The Event

Event poster

ESC Congress 2023

26 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9i: expanding benefits across the spectrum of cardiovascular disease
thumbnail
Congress Presentation
Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention
thumbnail
Congress Session
PCSK9 inhibitors for acute coronary syndromes: the era of early implementation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources